CMPX

Compass Therapeutics, Inc. (CMPX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics. The company operates in a single segment focused on research and development (R&D) of four primary product candidates: tovecimig (lead candidate), CTX-471, CTX-8371, and CTX-10726. The company has not generated any product revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose by $5.9 million (28%) in Q2 2026 compared to Q2 2025. This was driven by a $3.2 million increase in R&D expenses and a $2.8 million increase in General and Administrative (G&A) expenses.
• R&D Drivers: The increase in R&D was primarily due to $2.6 million in non-personnel project expenses for the lead candidate, tovecimig, and increased stock-based compensation.
• G&A Drivers: G&A expenses increased due to $1.4 million in pre-commercialization expenses and $0.8 million in additional stock-based compensation.
• Share Count: Weighted average shares outstanding increased significantly from 138.3 million in Q2 2025 to 186.8 million in Q2 2026, largely due to the inclusion of pre-funded warrants from the August 2025 offering.
• Investment Portfolio: Marketable securities decreased from $178.3 million at year-end 2025 to $144.4 million at June 30, 2026, reflecting net sales of securities to fund operations.

Outlook, Guidance, and Risks

• Liquidity Outlook: Management expects current cash resources ($180 million) to fund operating expenses and capital expenditures into 2028. No specific revenue guidance is provided as the company has no commercial products.
• Clinical Developments:
  • Tovecimig: Met primary endpoint (ORR) in the COMPANION-002 Phase 2/3 study for biliary tract cancer. FDA feedback is expected in Q3 2026 prior to a potential Biologics License Application (BLA) filing later in 2026.
  • CTX-8371: Phase 1 expansion cohorts are enrolling for TNBC, Hodgkin lymphoma, and NSCLC. Data expected in Q4 2026.
  • CTX-10726: Phase 1 dose-escalation study has begun dosing patients.
• Risks:
  • Capital Needs: The company will require substantial additional funding to complete clinical development and commercialization. Failure to raise capital could force delays or elimination of programs.
  • Regulatory Uncertainty: No assurance that product candidates will obtain regulatory approval or be commercially viable.
  • Macroeconomic Factors: Risks include inflation, interest rate hikes, and new U.S. tariffs (10-12.5% on imports) which may increase R&D costs for raw materials and equipment.

Key Investor Verification Points

• BLA Filing Timeline: Verify the timing of the FDA feedback in Q3 2026 and the subsequent BLA filing for tovecimig, as this is the primary catalyst for potential revenue.
• Burn Rate Sustainability: Confirm that the $180 million cash runway is sufficient to reach 2028 given the increasing R&D spend ($33 million YTD) and potential need for additional capital raises.
• Stock-Based Compensation: Monitor the $45.8 million in remaining unrecognized stock-based compensation, which will continue to impact future operating expenses.
• Pre-Funded Warrants: Note that 6.71 million pre-funded warrants are included in the share count for EPS calculations, diluting per-share metrics.
• Tariff Impact: Assess the potential impact of new U.S. import tariffs on the cost of active pharmaceutical ingredients and manufacturing.